Press Release: aap submits CE marking application for its innovative antibacterial silver coating technology

aap Implantate AG / aap submits CE marking application for its innovative antibacterial silver coating technology . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) announces that the design dossier for the performance of a CE conformity assessment procedure for the antibacterial silver coating technology developed by the company was recently submitted to a notified body leading in the field of medical products. The conformity assessment procedure will initially be undertaken for a silver-coated LOQTEQ(R) plate. In case of a successful conformity assessment, the company plans to extend the approval to further trauma products.

aap

Implantate AG's silver coating technology addresses infection prevention, which is one of the critical problems in surgery that haven't yet been resolved adequately. During a procedure medical implants can become colonized by bacteria from the surrounding area forming a biofilm thereafter which can cause serious infections later. Both antibiotics and the human immune system have only a very limited effect against biofilms. It is therefore desirable to combat the biofilm formation at an early stage. This is where aap

Implantate AG's silver coating technology becomes effective by protecting the implants' surface against bacterial colonisation. As there are no considerable resistances against silver the coating also protects against the colonisation by the particular problematic multiresistant germs.

The unique selling propositions of the silver coating technology developed by aap

Implantate AG have been demonstrated in diverse trials and consist of the high coating stability as well as the good biocompatibility and effectiveness. It is furthermore a cost-efficient coating technology due to the relatively short coating time and the comparatively low capital investment for the required coating machines.

Overall aap

Implantate AG's silver coating technology has a wide range of applications as a platform technology and can in a next step be used inter alia in other areas such as cardiology and dentistry or for a variety of medical instruments.

By submitting the design dossier for the performance of a CE conformity assessment procedure for the silver coating technology aap

Implantate AG makes important progress regarding its strategic objective to accelerate value-based innovations.

About aap Implantate AG

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma and biomaterials products for orthopedics. The trauma portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws as well as standard plates and screws. In the biomaterials business the company is specialized on bone cements and mixing systems. In German-speaking countries aap Implantate AG directly sells its trauma products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 60 countries at the international level. In the biomaterials business sales are handled via OEM and private label cooperations with several selected international orthopedic and trauma companies. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

HUG#1981358

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.aap.de (END) Dow Jones Newswires

   January 26, 2016 08:44 ET (13:44 GMT)- - 08 44 AM EST 01-26-16